Association between cystatin C and major adverse cardiac events in patients with ischemic heart disease and type 2 diabetes mellitus after acute coronary syndrome
DOI:
https://doi.org/10.14739/2310-1210.2019.3.168962Keywords:
myocardial ischemia, type 2 diabetes mellitus, cystatin CAbstract
Purpose. To evaluate the level of cystatin C and its association with the risk of developing repeated major adverse cardiac events (MACE) in patients with ischemic heart disease (IHD) and preserved kidney function in combination with type 2 diabetes mellitus (DM) within 12 months after acute coronary syndrome (ACS).
Materials and methods. A total of 88 patients, aged 30–75 years, (59 patients with DM and 29 patients without DM) with prior ACS (unstable angina or myocardial infarction) in the previous 4–6 weeks were enrolled. The control group consisted of 15 healthy persons. The follow-up period was 11 months.
Results. Cystatin C level in patients with DM was higher than in patients without DM (2057.69 ± 107.56 ng/ml vs 1376.57 ± 81.11 ng/ml, P < 0.05). In patients with CHD without diabetes, the level of cystatin C was although higher than in the control group, but not statistically significantly (P > 0.05).
During the follow-up period, the MACE rate in DM patients was higher than in patients without DM, 40.68 % (n = 24) and 10.34 % (n = 3), respectively, P < 0.05. According to the ROC analysis, cystatin C level of more than 1942.62 ng/ml was associated with MACE occurrence in DM patients within 12 months after ACS, the sensitivity of the method was 82.60 %, specificity – 64.30 %. As a result of the multivariate regression analysis adjusted for age and sex, it has been identified that cystatin C was an independent predictor for MACE occurrence in DM patients within 12 months after ACS (OR 3ю78, 95 % CI [1.51, 7.41], P = 0.001).
Conclusions. Cystatin C was an independent predictor for MACE after ACS in patients with DM and preserved kidney function.
References
Cziraky, M. J., Reddy, V. S., Luthra, R., Xu, Y., Wilhelm, K., Power, T. P., & Fisher, M. D. (2015). Clinical Outcomes and Medication Adherence in Acute Coronary Syndrome Patients With and Without Type 2 Diabetes Mellitus: A Longitudinal Analysis 2006–2011. Journal of Managed Care & Specialty Pharmacy, 21(6), 470–477. doi: 10.18553/jmcp.2015.21.6.470
Dalby, A., Gottlieb, S., Cyr, D., Magnus Ohman, E., McGuire, D., Ruzyllo, W., et al. (2017). Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. American Heart Journal, 188, 156–166. doi: 10.1016/j.ahj.2017.03.015
De Servi, S., Mariani, G., Piatti, L., Leoncini, M., Rubartelli, P., Pitì, A., et al. (2014). Time course changes of cystatin C and inflammatory and biochemical markers in non-ST-elevation acute coronary syndromes. Journal of Cardiovascular Medicine, 15(1), 42–47. doi: 10.2459/JCM.0b013e328365a275
Palmer, S., Di Micco, L., Razavian, M., Craig, J., Perkovic, V., Pellegrini, F., et al. (2012). Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. Annals of Internal Medicine, 156(6), 445–59. doi: 10.7326/0003-4819-156-6-201203200-00007
Angiolillo, D., Bernardo, E., Capodanno, D., Vivas, D., Sabaté, M., Ferreiro, J., et al. (2010). Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 55(11), 1139–46. doi: 10.1016/j.jacc.2009.10.043
Zhang, Y., Li, M., Tang, J., & Chen, X. (2017). Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. International Journal of Environmental Research and Public Health, 14(3). pii: E301. doi: 10.3390/ijerph14030301
Mariani, M., Mariani, G., & De Servi, St. (2014) Clinical Significance of Cystatin C in Acute Coronary Syndromes: Something More Than a Marker of Renal Function?. Inflammation and Cell Signaling., 1(4), е. 229.
Angelidis, C., Deftereos, S., Giannopoulos, G., Anatoliotakis, N., Bouras, G., Hatzis, G., et al. (2013) Cystatin C: an emerging biomarker in cardiovascular disease. Current Topics in Medicinal Chemistry. Curr Top Med Chem, 13(2), 164–179. doi: 10.2174/1568026611313020006
Sai, E., Shimada, K., Miyauchi, K., Masaki, Y., Kojima, T., Miyazaki, T., et al. (2015). Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents. Heart and Vessels, 31(5), 694–701. doi: 10.1007/s00380-015-0674-0
Fu, Z., Xue, H., Guo, J., Chen, L., Dong, W., Gai, L., et al. (2013). Long-term prognostic impact of cystatin c on acute coronary syndrome octogenarians with diabetes mellitus. Cardiovascular Diabetology, 12, 157. doi: 10.1186/1475-2840-12-157
Fiseha, T. (2015). Clinical Significance of Cystatin C-Based Estimates of Renal Function in Type 2 Diabetic Patients: Review. Annals of Clinical and Laboratory Research, 3(2). doi: 10.21767/2386-5180.100011
Triki, S., Fekih, O., Hellara, I., Neffati, F., Douki, W., Hamda, K. B., et al. (2013). Association between serum cystatin C levels and cardiovascular disease in type 2 diabetic patients. Ann Biol Clin (Paris), 71(4), 438–42. doi: 10.1684/abc.2013.0857
Liu, F., Shen, J., Zhao, J., Zeng, H., Li, L., Zhao, J., et al. (2013). Cystatin C: A Strong Marker for Lower Limb Ischemia in Chinese Type 2 Diabetic Patients? PLoS ONE, 8(7), e66907. doi: 10.1371/journal.pone.0066907
Magnusson, M., Hedblad, B., Engström, G., Persson, M., Nilsson, P., & Melander, O. (2013). High levels of cystatin C predict the metabolic syndrome: the prospective Malmö Diet and Cancer Study. Journal of Internal Medicine, 274(2), 192–9. doi: 10.1111/joim.12051
Reutens, A., Bonnet, F., Lantieri, O., Roussel, R., & Balkau, B. (2013). The association between cystatin C and incident type 2 diabetes is related to central adiposity. Nephrol Dial Transplant, 28(7), 1820–1829. doi: 10.1093/ndt/gfs561
Magnusson, M., Molvin, J., Engström, G., Svensson-Färbom, P., Persson, M., Christensson, A., et al. (2016). Cystatin C and Risk of Diabetes and the Metabolic Syndrome – Biomarker and Genotype Association Analyses. PLOS ONE, 11(5), e0155735. doi: 10.1371/journal.pone.0155735
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., Feldman, H. I., et al. (2009). A new equation to estimate glomerular filtration rate. Ann Intern Med, 150(9), 604–612.
Hall, A., Håkansson, K., Mason, R. W., Grubb, A., & Abrahamson, M. (1995). Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases. Journal of Biological Chemistry., 270(10), 5115–5121. doi: 10.1074/jbc.270.10.5115
Angelidis, C., Deftereos, S., Giannopoulos, G., Anatoliotakis, N., Bouras, G., Hatzis, G., et al. (2013). Cystatin C: an emerging biomarker in cardiovascular disease. Current Topics in Medicinal Chemistry, 13(2), 164–179.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
